
Clinicians' Guides to Radionuclide Hybrid Imaging

PET/CT

Series Editors

Jamshed B. Bomanji
London, UK

Gopinath Gnanasegaran
London, UK

Stefano Fanti
Bologna, Italy

Homer A. Macapinlac
Houston, Texas, USA

More information about this series at <http://www.springer.com/series/13803>

Gary Cook
Editor

PET/CT in Prostate Cancer

 Springer

 **BNMS**
BRITISH NUCLEAR MEDICINE SOCIETY

Editor
Gary Cook
Department of Cancer Imaging
King's College London
London
United Kingdom

Clinicians' Guides to Radionuclide Hybrid Imaging - PET/CT
ISBN 978-3-319-57623-7 ISBN 978-3-319-57624-4 (eBook)
DOI 10.1007/978-3-319-57624-4

Library of Congress Control Number: 2017946023

© Springer International Publishing AG 2017

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Springer imprint is published by Springer Nature
The registered company is Springer International Publishing AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

*PET/CT series is dedicated to Prof Ignac
Fogelman, Dr Muriel Buxton-Thomas and
Prof Ajit K Padhy*

Foreword

Clear and concise clinical indications for PET/CT in the management of the oncology patient are presented in this series of 15 separate booklets.

The impact on better staging, tailored management and specific treatment of the patient with cancer has been achieved with the advent of this multimodality imaging technology. Early and accurate diagnosis will always pay, and clear information can be gathered with PET/CT on treatment responses. Prognostic information is gathered and can forward guide additional therapeutic options.

It is a fortunate coincidence that PET/CT was able to derive great benefit from radionuclide-labelled probes, which deliver good and often excellent target to non-target signals. Whilst labelled glucose remains the cornerstone for the clinical benefit achieved, a number of recent probes are definitely adding benefit. PET/CT is hence an evolving technology, extending its applications and indications. Significant advances in the instrumentation and data processing available have also contributed to this technology, which delivers high-throughput and a wealth of data, with good patient tolerance and indeed patient and public acceptance. As an example, the role of PET/CT in the evaluation of cardiac disease is also covered, with emphasis on labelled rubidium and labelled glucose studies.

The novel probes of labelled choline; labelled peptides, such as DOTATATE; and, most recently, labelled PSMA (prostate-specific membrane antigen) have gained rapid clinical utility and acceptance, as significant PET/CT tools for the management of neuroendocrine disease and prostate cancer patients, notwithstanding all the advances achieved with other imaging modalities, such as MRI. Hence, a chapter reviewing novel PET tracers forms part of this series.

The oncological community has recognised the value of PET/CT and has delivered advanced diagnostic criteria for some of the most important indications for PET/CT. This includes the recent Deauville criteria for the classification of PET/CT patients with lymphoma—similar criteria are expected to develop for other malignancies, such as head and neck cancer, melanoma and pelvic malignancies. For completion, a separate section covers the role of PET/CT in radiotherapy planning, discussing the indications for planning biological tumour volumes in relevant cancers.

These booklets offer simple, rapid and concise guidelines on the utility of PET/CT in a range of oncological indications. They also deliver a rapid aide-memoire on the merits and appropriate indications for PET/CT in oncology.

London, UK

Peter J. Ell, FMedSci, DR HC, AΩA

Preface

Hybrid imaging with PET/CT and SPECT/CT combines best of function and structure to provide accurate localisation, characterisation and diagnosis. There is extensive literature and evidence to support PET/CT, which has made significant impact in oncological imaging and management of patients with cancer. The evidence in favour of SPECT/CT especially in orthopaedic indications is evolving and increasing.

The *Clinicians' Guides to Radionuclide Hybrid Imaging* (PET/CT and SPECT/CT) pocketbook series is specifically aimed at our referring clinicians, nuclear medicine/radiology doctors, radiographers/technologists and nurses who are routinely working in nuclear medicine and participate in multidisciplinary meetings. This series is the joint work of many friends and professionals from different nations who share a common dream and vision towards promoting and supporting nuclear medicine as a useful and important imaging speciality.

We want to thank all those people who have contributed to this work as advisors, authors and reviewers, without whom the book would not have been possible. We want to thank our members from the BNMS (British Nuclear Medicine Society, UK) for their encouragement and support, and we are extremely grateful to Dr. Brian Nielly, Charlotte Weston, the BNMS Education Committee and the BNMS council members for their enthusiasm and trust.

Finally, we wish to extend particular gratitude to the industry for their continuous support towards education and training.

London, UK

Gopinath Gnanasegaran
Jamshed Bomanji

Acknowledgements

The series coordinators and editors would like to express sincere gratitude to the members of the British Nuclear Medicine Society, patients, teachers, colleagues, students, the industry and the BNMS Education Committee members, for their continued support and inspiration:

Andy Bradley
Brent Drake
Francis Sundram
James Ballinger
Parthiban Arumugam
Rizwan Syed
Sai Han
Vineet Prakash

Contents

1	Epidemiology and Clinical Features	1
	Nikolaos Tsoukalas and Sarah Rudman	
2	Pathology of Prostate Cancer	11
	Ashish Chandra	
3	Management of Prostate Cancer	19
	Simon Hughes and Ajay Aggarwal	
4	Prostate Cancer: Radiological Imaging	27
	Vicky Goh and Giles Rottenberg	
5	The Role of PET/CT in Prostate Cancer Management	33
	Benjamin Taylor, Anna Paschali, Vineet Pant, Ishita B. Sen, and Gary Cook	
6	Role of Radiolabelled Small Molecules Binding to PSMA in Diagnosis and Therapy of Prostate Cancer	51
	Uwe Haberkorn, Matthias Eder, Klaus Kopka, John W. Babich, and Michael Eisenhut	
	Index	59

Contributors

John W. Babich Department of Radiopharmacy, Weill Cornell Medical College, New York, NY, USA

Ashish Chandra Guys and St Thomas' NHSFT, London, UK

Matthias Eder Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany

Michael Eisenhut Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany

Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany

Vicky Goh Department of Cancer Imaging, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK

Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK

Uwe Haberkorn Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany

Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany

Simon Hughes Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK

Klaus Kopka Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany

Vineet Pant Nuclear Medicine Fortis Memorial Research Institute, Gurgaon, India

Anna Paschali Clinical PET Centre, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK

Giles Rottenberg Department of Radiology, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK

Sarah Rudman Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK

Ishita B. Sen Nuclear Medicine Fortis Memorial Research Institute, Gurgaon, India

Benjamin Taylor Department of Cancer Imaging, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK

Nikolaos Tsoukalas Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK